Newly prequalified Active Pharmaceutical Ingredient (API)
Protionamide (WHOAPI-284) manufactured by Mylan Laboratories Ltd ha
Protionamide (WHOAPI-284) manufactured by Mylan Laboratories Ltd ha
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list:
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list:
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list:
Etravirine (WHOAPI-280) manufactured by Mylan Laboratories Ltd has
WHO Prequalification Team: medicines (PQTm) added the below new products to its prequalified list:
WHO Prequalification Team: medicines (PQTm) added the below new products to its prequalified list
WHO Prequalification Team: medicines (PQTm) added the below new products to its prequalified list:
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list:
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list:
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list:
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list:
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list
Pyrimethamine (WHOAPI-278) and sulfadoxine (WHOAPI-279) manufactured by Gu
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list
The following products were added:
WHO Prequalification wishes to announce the prequalification of three new prequalified APIs, namely:
This year WHO will launch a pilot project for prequalifying biosimilar medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and midd
Artemether (WHOAPI-268) manufactured by Chongqing Holley Wuling Mountain Pharmaceutical Co Ltd and Darunavir (ethanolate) (WHOAPI-214) ma
The lack of prequalified reproductive health medicines is of great concern to WHO and to partner organizations working to improve reproductive health.
Agreement seeks to improve health options for hepatitis C patients in low- and middle-income countries.
WHO Prequalification Team - Medicines (PQT) added the below new products to its prequalified list
WHO Prequalification Team - Medicines (PQT) added the below new products to its prequalified list
WHO Prequalification Team - Medicines (PQT) added the below new products to its prequalified list
The following products were added:
On 31 March 2017, WHO for the first time prequalified a generic active pharmaceutical ingredient (API) for hepatitis C – sofosbuvir.
Sofosbuvir (WHOAPI-290) manufactured by
The Prequalification Team is publishing a request for proposals for consultancy services relating to - developing and maintaining the Quality Management Systems (QMS) and assuming the responsibilit
Applicants and Contract Research Organizations (CROs) performing bioequivalence studies are reminded that all studies with human subjects must be conducted in compliance with Good Clinical Practice